ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Pilot Evaluation of Prognosis After Liver Transplantation in Patients with a History of Hepatocellular Carcinoma and Pd-1 Inhibition

M. Chen1, Z. Chen1, X. Lin2

1First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, 2the Eastern Hospital of the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

Meeting: 2021 American Transplant Congress

Abstract number: 1112

Keywords: Drug interaction, Rejection, Tumor recurrence

Topic: Clinical Science » Liver » Liver: Hepatocellular Carcinoma and Other Malignancies

Session Information

Session Name: Liver: Hepatocellular Carcinoma and Other Malignancies

Session Type: Poster Abstract

Session Date & Time: None. Available on demand.

Location: Virtual

*Purpose: The successful applications of programmed death protein-1 (PD-1) inhibitors in cancer therapy has led to an expanding use of immunotherapy in oncolog Liver transplantation (LT) is considered the most effective treatment for end stage liver diseases (ESLD) including HCC. However, the applications of PD-1 inhibitors in cancer patients would be controversial with LT. In this article, we have firstly described the clinical characteristics, imaging findings, and outcomes of 5 LT patients who had a History of HCC and PD-1 Inhibition.

*Methods: Data of 5 cases who were diagnosed with HCC and received a LT after applications of PD-1 inhibition were analyzed. Doses and cycles of PD-1, preoperative and postoperative characteristics were compared and analyzed.

*Results: The mean time difference between the last treatment of PD-1 inhibition and LT was 63.80±18.26 days. One patient had a recurrence in liver, vertebrae and lungs after 7 months. All patients displayed normal liver function in the latest follow-up. No acute allograft rejections were occurred in all patients.

*Conclusions: PD-1 inhibitor may be safe to be used tin the treatment of HCC before LT when the time difference is sufficient. Further investigations are needed for any convincing results.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Chen M, Chen Z, Lin X. Pilot Evaluation of Prognosis After Liver Transplantation in Patients with a History of Hepatocellular Carcinoma and Pd-1 Inhibition [abstract]. Am J Transplant. 2021; 21 (suppl 3). https://atcmeetingabstracts.com/abstract/pilot-evaluation-of-prognosis-after-liver-transplantation-in-patients-with-a-history-of-hepatocellular-carcinoma-and-pd-1-inhibition/. Accessed May 31, 2025.

« Back to 2021 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences